169 related articles for article (PubMed ID: 17269159)
1. The antibacterial drugs market.
Kresse H; Belsey MJ; Rovini H
Nat Rev Drug Discov; 2007 Jan; 6(1):19-20. PubMed ID: 17269159
[No Abstract] [Full Text] [Related]
2. The urgent need for new antibacterial agents.
Wise R;
J Antimicrob Chemother; 2011 Sep; 66(9):1939-40. PubMed ID: 21700627
[No Abstract] [Full Text] [Related]
3. Antibiotics at the crossroads.
Nathan C
Nature; 2004 Oct; 431(7011):899-902. PubMed ID: 15496893
[No Abstract] [Full Text] [Related]
4. Antibiotics: a shot in the arm.
Leeb M
Nature; 2004 Oct; 431(7011):892-3. PubMed ID: 15496888
[No Abstract] [Full Text] [Related]
5. The antibiotic pipeline--challenges, costs, and values.
Wenzel RP
N Engl J Med; 2004 Aug; 351(6):523-6. PubMed ID: 15295041
[No Abstract] [Full Text] [Related]
6. Antibacterial drug discovery: is it all downhill from here?
Projan SJ; Shlaes DM
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
[TBL] [Abstract][Full Text] [Related]
7. Where does novel antibiotics R&D stand among other pharmaceutical products: an industrial perspective?
Tillotson GS
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):551-2. PubMed ID: 18847393
[No Abstract] [Full Text] [Related]
8. Update on the antibacterial resistance crisis.
Croft AC; D'Antoni AV; Terzulli SL
Med Sci Monit; 2007 Jun; 13(6):RA103-18. PubMed ID: 17534243
[TBL] [Abstract][Full Text] [Related]
9. Monopoly pricing of an antibiotic subject to bacterial resistance.
Herrmann M
J Health Econ; 2010 Jan; 29(1):137-50. PubMed ID: 20015559
[TBL] [Abstract][Full Text] [Related]
10. Stepping up to the plate.
Nat Immunol; 2008 Jan; 9(1):1. PubMed ID: 18087245
[No Abstract] [Full Text] [Related]
11. The role of the pharmaceutical industry in meeting the public health threat of antibacterial resistance.
Bergström R
Drug Resist Updat; 2011 Apr; 14(2):77-8. PubMed ID: 21493123
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic development: a victim of market forces?
Tillotson GS
IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
[TBL] [Abstract][Full Text] [Related]
14. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial R&D incentives.
Laxminarayan R; Powers JH
Nat Rev Drug Discov; 2011 Sep; 10(10):727-8. PubMed ID: 21959280
[No Abstract] [Full Text] [Related]
16. A call to arms.
Nat Rev Drug Discov; 2007 Jan; 6(1):8-12. PubMed ID: 17269158
[No Abstract] [Full Text] [Related]
17. Emerging drugs for bacterial urinary tract infections.
Wagenlehner FM; Weidner W; Naber KG
Expert Opin Emerg Drugs; 2005 May; 10(2):275-98. PubMed ID: 15934867
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial drug discovery: is small pharma the solution?
Boggs AF; Miller GH
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():32-6. PubMed ID: 15522038
[TBL] [Abstract][Full Text] [Related]
19. The bacteria fight back.
Taubes G
Science; 2008 Jul; 321(5887):356-61. PubMed ID: 18635788
[No Abstract] [Full Text] [Related]
20. Drug companies snub antibiotics as pipeline threatens to run dry.
Clarke T
Nature; 2003 Sep; 425(6955):225. PubMed ID: 13679874
[No Abstract] [Full Text] [Related]
[Next] [New Search]
